Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Cessation of Mr. Sachin Jain as Chief Financial Officer of the company w.e.f. July 08, 2025.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals has informed stock exchanges that Mr. Sachin Jain has ceased to be the Chief Financial Officer of the company, effective July 08, 2025. The company has discontinued his services during his probation period — meaning he did not complete his probation and was relieved by the company. The filing is made under SEBI's Listing Regulations (Regulation 30) and includes standard Annexure-A details confirming the date of cessation and the reason. No replacement appointment has been announced in this filing.
The departure of a CFO during probation raises governance questions for shareholders, as the finance leadership role is now vacant. Investors should watch for an immediate announcement regarding a new CFO appointment; until then, there may be short-term uncertainty around financial reporting continuity, though the company has not indicated any financial irregularity.